id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-309786-8zyf9e3k	Karron, Ruth A	Safety and Immunogenicity of the Respiratory Syncytial Virus Vaccine RSV/ΔNS2/Δ1313/I1314L in RSV-Seronegative Children	2019-10-12		.txt	text/plain	4868	229	45	RESULTS: In RSV-seronegative children, the 10(5) PFU dose was overattenuated, but the 10(6) PFU dose was well tolerated, infectious (RSV/ΔNS2/Δ1313/I1314L replication detected in 90% of vaccinees), and immunogenic (geometric mean serum RSV plaque-reduction neutralizing antibody titer, 1:64). b A >4 fold-rise in serum RSV neutralizing antibody was detected in a placebo recipient in the 10 5 PFU dose cohort, probably indicating infection with wild-type RSV between study days 28 and 56. b A >4 fold-rise in serum RSV neutralizing antibody was detected in a placebo recipient in the 10 5 PFU dose cohort, probably indicating infection with wild-type RSV between study days 28 and 56. Live respiratory syncytial virus (RSV) vaccine candidate containing stabilized temperature-sensitivity mutations is highly attenuated in RSV-seronegative infants and children	./cache/cord-309786-8zyf9e3k.txt	./txt/cord-309786-8zyf9e3k.txt